What is the list of Angiotensin II Receptor Blockers (ARBs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Complete List of Angiotensin II Receptor Blockers (ARBs)

Angiotensin II Receptor Blockers (ARBs) include azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan. 1, 2

Available ARBs and Dosing Information

ARBs are a class of medications that block the effects of angiotensin II by antagonizing the angiotensin II type 1 receptor, leading to vasodilation and decreased blood pressure 2.

Currently Available ARBs:

  • Azilsartan: 40-80 mg once daily 1
  • Candesartan: 8-32 mg once daily 1
  • Eprosartan: 600-800 mg once or twice daily 1
  • Irbesartan: 150-300 mg once daily 1
  • Losartan: 50-100 mg once or twice daily 1
  • Olmesartan: 20-40 mg once daily 1
  • Telmisartan: 20-80 mg once daily 1, 3
  • Valsartan: 80-320 mg once daily 1

Pharmacological Properties of ARBs

ARBs differ in their pharmacokinetic and pharmacodynamic properties:

  • Prodrugs: Azilsartan, candesartan, and olmesartan are administered as prodrugs that require activation 2
  • Active metabolites: Losartan has an active metabolite (EXP3174) that contributes significantly to its antihypertensive effect 4
  • Bioavailability: Ranges from 13% (eprosartan) to 60-80% (irbesartan) 4
  • Protein binding: Most ARBs have high plasma protein binding (95-100%), with irbesartan having the lowest (90%) 4
  • Duration of action: All currently available ARBs provide 24-hour blood pressure control with once-daily dosing 5

Clinical Applications

ARBs are indicated for:

  • Hypertension: All ARBs are FDA-approved for treatment of hypertension 1, 3, 6
  • Heart failure: Candesartan, losartan, and valsartan have demonstrated benefits in heart failure 1
  • Diabetic nephropathy: ARBs reduce microalbuminuria and improve renal function in diabetic patients 1
  • Cardiovascular risk reduction: Some ARBs, like telmisartan, are indicated for cardiovascular risk reduction in patients unable to take ACE inhibitors 3

Advantages and Side Effects

Advantages:

  • Alternative to ACE inhibitors: ARBs are particularly useful in patients who develop cough or angioedema with ACE inhibitors 1, 5
  • Tolerability: ARBs generally have a side effect profile similar to placebo 5

Side Effects and Precautions:

  • Hyperkalemia: Increased risk in patients with CKD or those on potassium-sparing medications 1
  • Renal dysfunction: Risk of acute renal failure in patients with severe bilateral renal artery stenosis 1
  • Pregnancy: All ARBs should be avoided during pregnancy due to fetal toxicity 1, 6
  • Angioedema: Although less common than with ACE inhibitors, angioedema can still occur with ARBs 1

Comparative Efficacy

While all ARBs effectively lower blood pressure, some studies suggest differences in potency:

  • Based on daily mg dose, the relative potency follows: candesartan > telmisartan ≈ losartan > irbesartan ≈ valsartan > eprosartan 4
  • Head-to-head trials have suggested that olmesartan may provide greater blood pressure reduction than losartan, valsartan, irbesartan, and candesartan at their respective recommended doses 7

ARBs remain an important class of medications for cardiovascular and renal protection, with their specific selection often guided by comorbidities, dosing convenience, and individual patient response 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.